Welcome to our dedicated page for Nutex Health news (Ticker: NUTX), a resource for investors and traders seeking the latest updates and insights on Nutex Health stock.
Nutex Health Inc (NASDAQ: NUTX), a physician-led healthcare innovator, operates a unique dual-division model combining micro-hospitals with population health management. This page provides real-time access to official company announcements, financial disclosures, and strategic developments.
Investors and industry observers will find a centralized resource for earnings reports, partnership announcements, and updates on the company’s technology-driven care models. Track NUTX’s progress in expanding its network of concierge-style emergency centers and risk-bearing provider networks.
All content is sourced directly from verified corporate communications, ensuring accuracy for those analyzing healthcare sector trends or monitoring the company’s integration of cloud-based data platforms with clinical operations. Regular updates reflect NUTX’s commitments to operational transparency and community-focused care delivery.
Bookmark this page for efficient tracking of Nutex Health’s milestones in redefining emergency medicine and value-based care through its specialty hospitals and population health initiatives.
Nutex Health (NASDAQ: NUTX) announced its Board has extended a previously authorized $25.0 million common stock repurchase program through March 31, 2026. The program, first authorized Aug 14, 2025, began upon filing the Form 10-Q for the quarter ended June 30, 2025 and will be executed under Rule 10b-18 and a Rule 10b5-1 trading plan scheduled to take effect on or about Dec 4, 2025. The company said the buyback aims to increase shareholder value and offset dilution from stock compensation for under-construction and ramping hospitals. Repurchases remain discretionary and may be affected by market, financial, legal and capital considerations.
Nutex Health (NASDAQ: NUTX) announced the reopening of Red River ER & Hospital in Sherman, Texas on November 24, 2025. The 18,500 sq ft facility offers 24/7/365 concierge-level care with seven ER beds, four inpatient suites, and two triage rooms. The site includes a full-service laboratory and advanced imaging (MRI, CT, X-ray, ultrasound) with same-day scheduling and rapid results.
Company leaders highlighted the hospital's role serving the growing Sherman area and nearby Oklahoma communities and emphasized upgraded equipment, reduced wait times, and around-the-clock clinical staffing.
Nutex Health (NASDAQ: NUTX) reported strong results for the three and nine months ended September 30, 2025, driven by the hospital division and arbitration recoveries. Nine‑month revenue was $723.6M, up 225.5% versus 2024, with hospital revenue of $700.5M (up 251.4%). Net income attributable to Nutex Health was $59.0M for nine months versus a $9.5M loss in 2024. EBITDA was $142.9M and Adjusted EBITDA was $243.0M for nine months. Cash and cash equivalents totaled $166.0M and net cash from operating activities was $177.7M for the nine months. The company noted substantial stock‑based compensation of $119.6M and significant reliance on IDR arbitration recoveries (≈66% of hospital revenue for nine months).
Nutex Health (NASDAQ: NUTX) reported strong first-half 2025 results: total revenue $455.8M versus $143.5M (+217.5%), net income attributable $3.5M vs a $0.7M loss, and diluted EPS $0.55. Adjusted EBITDA $144.4M (vs $6.4M), and EBITDA $51.1M. Cash balance was a record $96.7M and net cash from operations was $78.2M. Hospital division visits reached 93,842 (+15.5% YTD). The board authorized an opportunistic $25.0M share repurchase program on August 14, 2025. Total stock-based compensation was $106.4M for H1 2025, primarily for under-construction and ramping hospitals. Total assets were $841.0M as of June 30, 2025.
NUTEX HEALTH (NASDAQ: NUTX) reported restated Q1 2025 results for the quarter ended March 31, 2025, including a 214.0% increase in total revenue to $211.8M and net income attributable to Nutex of $21.2M versus a $0.4M loss in Q1 2024. EBITDA was $51.5M and Adjusted EBITDA was $72.8M. The company recorded $27.6M of stock-based compensation (≈99% related to under-construction and ramping hospitals).
The restatement corrected non-cash classifications (stock-based compensation reclassified from equity to liabilities, related-party payables reclassified to equity, $2.9M moved to short-term investments, and accrued income tax expense increased $2.4M). Total liabilities rose by $19.6M (4.0%), total equity declined $19.6M (7.1%), and net income for the period increased by $6.6M (14.9%) on the restated basis. Cash and cash equivalents were $84.7M and net cash from operating activities was $51.0M.
NUTEX HEALTH (NASDAQ: NUTX) reported restated full-year and Q4 2024 results on Nov 18, 2025 reflecting non-cash reclassifications and immaterial net-income impact.
Key 2024 metrics: total revenue $479.9M (+93.8% vs 2023); net income attributable $52.1M vs loss $45.8M in 2023; diluted EPS $9.69; EBITDA $98.8M; Adjusted EBITDA $124.1M. Q4 revenue $257.6M (+269.8% YoY); Q4 net income $61.6M.
Restatement adjustments reclassified $16.4M of stock‑based compensation to liabilities, moved $3.5M related‑party payables to equity, shifted $2.9M to short‑term investments, and increased accrued tax by $0.5M; total liabilities rose $13.4M (2.9%).
NUTEX HEALTH (NASDAQ: NUTX) appointed Wesley Bamburg as Chief Operating Officer, effective October 13, 2025. Bamburg brings 20 years of Fortune 500 healthcare experience and prior COO roles at HCA Houston Healthcare Medical Center (2019–2024) and HCA Houston Healthcare North Cypress (since July 2024).
The company said Bamburg's background in operations, payor contracting, integrated network management, and physician relations will support Nutex Health's physician-led micro hospital and outpatient expansion across 11 states.
Nutex Health (NASDAQ: NUTX) reported preliminary Q3 2025 operational metrics showing patient volume up 11.1% year‑over‑year (46,293 visits vs. 41,668) and a cash collections increase of 258.8% in Q3 2025 ($235,003k vs. $65,501k). Year‑to‑date patient visits rose 14.0% and YTD cash collections increased 176.9%. Management labels these figures as preliminary estimates subject to final accounting adjustments.
The company disclosed an ongoing restatement related to accounting for earn‑out obligations from a 2022 merger, leading to previously issued statements being unreliable, a Nasdaq non‑compliance notice, and a Nasdaq‑granted exception to file the delinquent Form 10‑Q for June 30, 2025 by December 12, 2025. The Q3 2025 Form 10‑Q will be filed after completing the restatement and related filings.
Nutex Health (NASDAQ: NUTX) announced it earned a record‑breaking 20 awards and honors in the third quarter of 2025, the most in company history, the PR states.
The awards span its network of 24 micro hospitals and HOPDs across 11 states and include community‑voted recognitions for emergency care, hospitals, pediatric services, workplace, CIHQ accreditation at multiple facilities, and a corporate Horizon Award for patient financial experience.
FAQ
What is the current stock price of Nutex Health (NUTX)?
What is the market cap of Nutex Health (NUTX)?
